根据中国证券监督管理委员会《上市公司监管指引第 2 号——上市公司募集 资金管理和使用的监管要求》和《上海证券交易所科创板上市公司自律监管指引 第 1 号——规范运作》《上海证券交易所科创板股票上市规则》等有关规定，杭 州安杰思医学科技股份有限公司（以下简称"公司""安杰思"或"本公司"） 编制了《2023 年年度募集资金存放与使用情况的专项报告》。具体如下： 一、募集资金基本情况 证券代码：688581 证券简称：安杰思 公告编号：2024-017 杭州安杰思医学科技股份有限公司 2023 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 （一）实际募集资金金额和资金到账时间 根据中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司 首次公开发行股票注册的批复》（证监许可〔2023〕481号），同意公司首次公 开发行股票的注册申请。并经上海证券交易所同意，公司首次向社会公开发行人 民币普通股（A股）股票1,447.00万股，本次发行价格为每股人民币125.80元， 募集资 ...

Financial Performance - The company's operating revenue for 2023 reached ¥508.75 million, representing a year-on-year increase of 37.09% compared to ¥371.11 million in 2022[22]. - The net profit attributable to shareholders for 2023 was ¥217.24 million, a 49.86% increase from ¥144.96 million in the previous year[22]. - The net profit after deducting non-recurring gains and losses was ¥212.02 million, reflecting a 48.35% growth compared to ¥142.92 million in 2022[22]. - The company's operating cash flow increased by 41.61% year-on-year, reaching ¥221,447,224.50, driven by rapid revenue growth and increased cash receipts from sales[24]. - Basic earnings per share rose by 25.46% to ¥4.1904, while diluted earnings per share increased by 25.41% to ¥4.1887, reflecting the overall growth in net profit[25]. - The company's revenue grew by 37.09% year-on-year, driven by strong market expansion in China and the United States, with rapid sales growth in GI, ERCP, and ESD/EMR product categories[25]. - The company achieved operating revenue of CNY 508.75 million, a year-on-year increase of 37.09%[103]. - Net profit attributable to shareholders reached CNY 217.24 million, up 49.86% compared to the previous year[103]. Dividend and Share Distribution - The company plans to distribute a cash dividend of 14.5 RMB per 10 shares and issue 4 bonus shares per 10 shares, with a total cash dividend amounting to approximately 83.33 million RMB, representing 38.36% of the net profit attributable to shareholders[5]. - The total share capital after the distribution will increase to approximately 80.86 million shares[5]. - The annual profit distribution plan has been approved by the board and will be submitted for shareholder approval[6]. - The total number of shares after the proposed stock distribution will increase to 80,858,800 shares[188]. Research and Development - The company invested a total of 41.25 million yuan in R&D, accounting for 8.11% of the operating revenue, and completed 25 design improvements and 15 new product developments during the reporting period[39]. - The total R&D investment for the year reached ¥41,251,410.55, an increase of 31.13% compared to the previous year[78]. - The company has applied for 12 patents related to fiber imaging technology, which aims to achieve large-area high-definition imaging and early diagnosis of lesions[81]. - The company has made significant progress in developing a robotic assistant for flexible endoscopy, with 4 patents applied and the prototype testing completed[81]. - The company has authorized 38 patents and has 45 patents pending, with significant advancements in GI products, including FDA and CE certifications for various devices[82]. Market Expansion and Sales - Domestic sales revenue reached 261.47 million yuan, a year-on-year increase of 37.57%, while overseas sales revenue was 244.63 million yuan, up 36.78%[38]. - The company plans to continue expanding its global market presence, particularly in high-growth regions, to sustain revenue growth[26]. - The international marketing department added 35 new overseas customers, with a 35% increase in the number of new clients[43]. - The company maintained a strong market presence, with a 62.55% share of revenue from distribution sales, reflecting a year-on-year increase of CNY 9.64 million[109]. Governance and Compliance - The company has received a standard unqualified audit report from Tianjian Accounting Firm[5]. - The company has confirmed that all board members attended the board meeting[4]. - The company has implemented a stock incentive plan to enhance employee motivation and align it with operational goals[46]. - The company adhered to information disclosure regulations, providing timely and accurate updates on its operational status and significant events[154]. - The company held 8 board meetings during the year, with 4 conducted in person and 4 via a combination of in-person and communication methods[176]. Operational Risks and Mitigation - The company has detailed various operational risks and corresponding mitigation measures in the report[4]. - The report includes a forward-looking statement risk declaration, indicating that future plans do not constitute a commitment to investors[8]. - The company faces potential product quality risks that could harm its competitive edge and brand reputation, with strict adherence to quality systems to mitigate these risks[92]. - International trade tensions and exchange rate fluctuations, particularly with the Euro and USD, could adversely affect the company's export business and financial performance[93]. Employee and Talent Development - The total number of employees in the parent company and major subsidiaries is 592, with 312 in production, 55 in sales, 106 in technology, 12 in finance, and 107 in administration[185]. - The company emphasizes talent development and aims to attract external technical talent while enhancing the skills of existing employees through professional training[145]. - The number of R&D personnel increased from 95 to 105, with total R&D compensation rising from ¥18,575,783.53 to ¥24,938,511.47, reflecting a focus on innovation[85]. Product Development and Innovation - The company is actively involved in the development of minimally invasive diagnostic and therapeutic technologies, including endoscopic systems and robotic-assisted surgery[16]. - The company launched innovative products, including a new hemostatic clip and a coating guide wire, aimed at reducing clinical costs and improving procedural success rates[41]. - The company is focusing on enhancing its product capabilities and specifications to provide comprehensive diagnostic solutions for early cancer treatment[81]. Financial Management - The company reported a significant increase in financial expenses, with a rise of 105.43% due to increased interest income[121]. - Cash and cash equivalents reached CNY 1,954,739,150.26, accounting for 83.86% of total assets, with a 45.10% increase compared to the previous period[122]. - The company’s financing activities generated a net cash flow of CNY 1.60 billion, primarily from the proceeds of its initial public offering[104]. Strategic Initiatives - The company is exploring potential mergers and acquisitions to bolster its competitive position in the industry[162]. - The company plans to enhance its digital marketing efforts, allocating 25% more budget towards online advertising campaigns[162]. - The company aims to improve operational efficiency by 10% through strategic initiatives in the next fiscal year[162].

证券代码：688581 证券简称：安杰思 公告编号：2024-016 杭州安杰思医学科技股份有限公司 关于续聘会计师事务所的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 拟聘任的会计师事务所名称：天健会计师事务所（特殊普通合伙）（以下 简称"天健"） | 事务所名称 | | | | 天健会计师事务所（特殊普通合伙） | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 成立日期 | 2011 7 月 | 年 | 18 | 日 | | 组织形式 | | | 特殊普通合伙 | | | | 注册地址 | | | | 浙江省杭州市西湖区灵隐街道西溪路 | | | 128 | 号 | | | | | 首席合伙人 | 王国海 | | | | | 上年末合伙人数量 | | | 238 | 人 | | | 上年末执业人 | 注册会计师 | | | | | | | | 2,272 | | ...

杭州安杰思医学科技股份有限公司 董事会审计委员会对 2023 年度会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》《上海证券交易所科创板 上市公司自律监管指引第1 号 -- 规范运作》和《公司章程》《审计委员会议事 规则》等规定和要求,杭州安杰思医学科技股份有限公司(以下简称"公司") 董事会审计委员会本着勤勉尽责的原则,恪尽职守,认真履职。现将董事会审计 委员会对会计师事务所 2023 年度履行监督职责的情况汇报如下: 一、2023年年审会计师事务所基本情况 | 事务所名称 | 天健会计师事务所(特殊普通合伙) | | | | --- | --- | --- | --- | | 成立日期 | 2011年7月18日 | 组织形式 | 特殊普通合伙 | | 注册地址 | 浙江省杭州市西湖区灵隐街道西溪路 128 号 | | | | 王国海 首席合伙人 | | 上年末合伙人数量 | 238 人 | | 上年末执业人员 | 注册会计师 | | 2, 272 人 | | 数量 | 签署过证券服务业务审计报告的注册 ...

2023 年度独立董事述职报告 作为杭州安杰思医学科技股份有限公司(以下简称"公司")的独立董事, 我严格按照《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人 民共和国证券法》(以下简称"《证券法》")、《上市公司独立董事管理办法》 等法律法规,以及《公司章程》和《杭州安杰思医学科技股份有限公司独立董事 制度》等有关规定和要求,本着客观、公正、独立的原则,勤勉尽责、独立履职, 及时通过多种途径了解公司生产经营、财务及公司相关发展情况,准时出席相关 会议,积极发挥独立董事作用,有效的维护公司整体利益和全体股东的合法权益。 现将我作为独立董事 2023年度履职情况报告如下: 一、 独立董事的基本情况 (一)个人工作履历、专业背景以及兼职情况 吴建海先生,中国国籍,无境外永久居留权,男,1979年7月出生,大学本 科学历,注册会计师。其主要经历如下:2001年6月至2006年10月,于浙江 天健会计师事务所有限公司任高级项目经理;2007年5月至2008年10月,于 阿里巴巴软件(上海)有限公司任会计主管;2008年 11月至 2016年 8月,于 宝鼎科技股份有限公司任董事、副总经理、财务总监、董事会 ...

目 录 募集资金年度存放与使用情况鉴证报告 天健审〔2024〕2820 号 杭州安杰思医学科技股份有限公司全体股东： 我们鉴证了后附的杭州安杰思医学科技股份有限公司（以下简称安杰思医学 公司）管理层编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 二、关于募集资金年度存放与使用情况的专项报告………………第 3—9 页 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 三、附件 ………………………………………………………… 第 10—13 页 （一）本所营业执照复印件……………………………………… 第 10 页 （二）本所从事证券服务业务备案完备证明材料……………… 第 11 页 （三）本所执业证书复印件……………………………………… 第 12 页 （四）注册会计师执业资格证书复印件………………………… 第 13 页 本鉴证报告仅供安杰思医学公司年度报告披露时使用，不得用作任何其他目 的。我们同意将本鉴证报告作为安杰思医学公司年度报告的必备文件，随同其他 文件一起报送并对外披露。 二、管理层的责任 安杰思医学公司管理层的责任是提供真实、 ...

Financial Performance - The company's operating revenue for Q1 2024 reached ¥111,561,373.32, representing a year-on-year increase of 23.35%[5] - Net profit attributable to shareholders was ¥52,781,143.37, reflecting a significant growth of 54.22% compared to the same period last year[5] - The net profit after deducting non-recurring gains and losses increased by 41.44% year-on-year, amounting to ¥48,270,105.04[5] - Total revenue for Q1 2024 reached ¥111,561,373.32, a 23.3% increase from ¥90,446,286.16 in Q1 2023[17] - Operating profit for Q1 2024 was ¥61,034,409.57, compared to ¥39,083,896.62 in Q1 2023, reflecting a growth of 56.2%[18] - Net profit for Q1 2024 amounted to ¥52,781,143.37, up 54.4% from ¥34,224,989.50 in Q1 2023[18] - Basic and diluted earnings per share for Q1 2024 were both ¥0.91, an increase from ¥0.79 in Q1 2023[19] Cash Flow - Cash flow from operating activities showed a net increase of 33.04%, totaling ¥14,279,053.92, driven by higher sales revenue and increased interest income[6] - In Q1 2024, cash inflow from operating activities totaled $132,589,555.25, an increase of 28.0% compared to $103,584,307.71 in Q1 2023[22] - Cash outflow from operating activities was $118,310,501.33, up from $92,851,779.47 in the same period last year, representing a 27.5% increase[22] - Net cash flow from operating activities reached $14,279,053.92, a 33.5% increase from $10,732,528.24 in Q1 2023[22] - The company reported a net decrease in cash and cash equivalents of $20,450,446.38 in Q1 2024, compared to a decrease of $6,008,132.33 in Q1 2023[23] Research and Development - Total R&D investment for the quarter was ¥11,493,491.83, marking a substantial increase of 64.47% year-on-year, with a focus on personnel and material costs[6] - R&D expenses accounted for 10.30% of operating revenue, up from 2.58% in the previous year, indicating a strategic emphasis on innovation[6] - Research and development expenses for Q1 2024 were ¥11,493,491.83, up 64.0% from ¥6,988,068.06 in Q1 2023[18] Assets and Liabilities - The company's total assets at the end of the quarter were ¥2,329,418,770.38, a slight decrease of 0.07% from the previous year[6] - Total assets as of the end of Q1 2024 were ¥2,329,418,770.38, slightly down from ¥2,331,074,065.19 at the end of Q1 2023[16] - Total liabilities decreased to ¥87,363,041.71 in Q1 2024 from ¥122,834,954.30 in Q1 2023, a reduction of 29%[16] Shareholder Information - Total number of common shareholders at the end of the reporting period is 5,128[11] - The largest shareholder, Hangzhou Yijia Investment Management Co., Ltd., holds 18,892,898 shares, accounting for 32.65% of total shares[11] - The top ten shareholders include several institutional investors, indicating a diverse ownership structure[12] Other Financial Metrics - Non-recurring gains and losses for the period totaled ¥4,511,038.33 after tax, primarily from government subsidies and other non-operating income[8] - The basic and diluted earnings per share for the quarter were both ¥0.91, reflecting a year-on-year increase of 15.19%[6] - The company has a repurchase account holding 260,398 shares, representing 0.45% of total share capital as of March 31, 2024[12] - The company has not reported any significant changes in the participation of major shareholders in securities lending activities[13] - There are no other significant reminders regarding the company's operational status during the reporting period[13] Financial Expenses - The company reported a financial expense of -¥12,758,263.94 in Q1 2024, compared to -¥97,374.35 in Q1 2023, indicating a significant change in financial performance[18] Cash and Cash Equivalents - Cash and cash equivalents are reported at ¥1,933,855,210.88, down from ¥1,954,739,150.26[14] - The ending balance of cash and cash equivalents was $1,934,281,703.88, up from $205,851,348.71 in Q1 2023[23] - The impact of exchange rate changes on cash and cash equivalents was $764,743.90, compared to a negative impact of -$499,329.57 in Q1 2023[23] Accounting Standards - The company has not adopted new accounting standards or interpretations for the year 2024[23]

中信证券股份有限公司 经中国证券监督管理委员会《关于同意杭州安杰思医学科技股份有限公司首 次公开发行股票注册的批复》（证监许可〔2023〕481 号）同意注册，并经上海 证券交易所同意，安杰思首次向社会公开发行人民币普通股（A 股）股票 1,447.0000 万股，发行价格为每股人民币 125.80 元，募集资金总额为人民币 182,032.60 万元，扣除发行费用人民币（不含增值税）16,931.32 万元后，实际募 集资金净额为人民币 165,101.28 万元。上述募集资金已于 2023 年 5 月 16 日全部 到位，并经天健会计师事务所（特殊普通合伙）审验，于 2023 年 5 月 17 日出具 了《验资报告》（天健验〔2023〕210 号）。 （二）募集资金使用和结余情况 单位：万元 | 项 目 | | 序号 | 金 | 额 | | --- | --- | --- | --- | --- | | 募集资金净额 | | A | | 165,101.28 | | 本期发生额 | 项目投入 | B1 | | 41,043.69 | | | 利息收入净额 | B2 | | 2,211.28 | | 应结余 ...

杭州安杰思医学科技股份有限公司 2023 年度会计师事务所履职情况评估报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《国有企业、上市 公司选聘会计师事务所管理办法》《上海证券交易所科创板上市公司自律监管指 引第 1 号 -- 规范运作》和《公司章程》等规定和要求,现将公司2023年度会 计师事务所的履职情况评估汇报如下: 一、2023年年审会计师事务所基本情况 根据《审计业务约定书》,遵循《中国注册会计师审计准则》和其他执业规 范,天健会计师事务所对公司 2023年度财务报告及 2023年12月 31日的财务报 告内部控制的有效性进行了审计,同时对公司 2023年度募集资金存放与实际使 用情况、2023 年度非经营性资金占用及其他关联资金往来情况等进行核查并出 具了专项报告。 在执行审计工作的过程中,天健会计师事务所就事务所和相关审计人员的独 立性、审计工作小组的人员构成、审计计划、风险判断、风险及舞弊的测试和评 价方法、年度审计重点、审计调整事项、初审意见等与公司董事会审计委员会、 独立董事以及公司管理层进行了沟通。经审查,公司认为天健会计师事务所在从 事公司年度审计服务过程中,尽职尽责,客观公 ...

公司代码：688581 公司简称：安杰思 杭州安杰思医学科技股份有限公司 2023 年度内部控制评价报告 杭州安杰思医学科技股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内 部控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专 项监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了 评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内 容不存在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别 及连带法律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整， 提高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标 提供合理保证。此外，由于情 ...